Choline acetyltransferase-expressing T cells are required to control chronic viral infection

Although widely studied as a neurotransmitter, T cell-derived acetylcholine (ACh) has recently been reported to play an important role in regulating immunity. However, the role of lymphocyte-derived ACh in viral infection is unknown. Here, we show that the enzyme choline acetyltransferase (ChAT), wh...

Full description

Saved in:
Bibliographic Details
Published inScience (American Association for the Advancement of Science) Vol. 363; no. 6427; pp. 639 - 644
Main Authors Cox, Maureen A, Duncan, Gordon S, Lin, Gloria H Y, Steinberg, Benjamin E, Yu, Lisa X, Brenner, Dirk, Buckler, Luke N, Elia, Andrew J, Wakeham, Andrew C, Nieman, Brian, Dominguez-Brauer, Carmen, Elford, Alisha R, Gill, Kyle T, Kubli, Shawn P, Haight, Jillian, Berger, Thorsten, Ohashi, Pamela S, Tracey, Kevin J, Olofsson, Peder S, Mak, Tak W
Format Journal Article
LanguageEnglish
Published United States The American Association for the Advancement of Science 08.02.2019
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Although widely studied as a neurotransmitter, T cell-derived acetylcholine (ACh) has recently been reported to play an important role in regulating immunity. However, the role of lymphocyte-derived ACh in viral infection is unknown. Here, we show that the enzyme choline acetyltransferase (ChAT), which catalyzes the rate-limiting step of ACh production, is robustly induced in both CD4 and CD8 T cells during lymphocytic choriomeningitis virus (LCMV) infection in an IL-21-dependent manner. Deletion of within the T cell compartment in mice ablated vasodilation in response to infection, impaired the migration of antiviral T cells into infected tissues, and ultimately compromised the control of chronic LCMV clone 13 infection. Our results reveal a genetic proof of function for ChAT in T cells during viral infection and identify a pathway of T cell migration that sustains antiviral immunity.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Present address: Department of Anesthesia and Pain Medicine, The Hospital for Sick Children, Toronto, ON M5G 1×8, Canada.
Present address: Trillium Therapeutics Inc., Mississauga, ON L5L 1J9, Canada.
Author contributions: Conceptualization, M.A.C. and T.W.M.; Methodology, M.A.C., T.W.M., L.X.Y., and B.N.; Investigation, M.A.C., G.S.D., G.H.Y.L., B.E.S., D.B., A.J.E., C.D.-B., S.P.K., T.B., L.N.B., L.X.Y., B.N., and R.F.; Writing-original draft, M.A.C.; Writing-review and editing, M.A.C., T.W.M., K.J.T., and P.S.O.; Resources, P.S.O., A.R.E., K.T.G., and J.H.; Visualization, M.A.C.; Supervision, T.W.M.; Funding acquisition, T.W.M.
ISSN:0036-8075
1095-9203
1095-9203
DOI:10.1126/science.aau9072